Revolution Medicines, Inc.
RVMD
$203.71
$1.710.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 68.41% | 65.39% | 66.55% | 62.67% | 54.79% |
| Gross Profit | -68.41% | -65.39% | -66.55% | -62.89% | -55.02% |
| SG&A Expenses | 159.00% | 139.93% | 101.64% | 79.65% | 62.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.31% | 75.68% | 71.48% | 65.02% | 55.82% |
| Operating Income | -81.31% | -75.68% | -71.48% | -65.22% | -56.02% |
| Income Before Tax | -117.55% | -96.45% | -88.28% | -69.70% | -55.49% |
| Income Tax Expenses | -- | -- | -- | -319.53% | 78.63% |
| Earnings from Continuing Operations | -117.75% | -96.66% | -88.52% | -69.47% | -56.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.75% | -96.66% | -88.52% | -69.47% | -56.40% |
| EBIT | -81.31% | -75.68% | -71.48% | -65.22% | -56.02% |
| EBITDA | -81.68% | -76.10% | -71.98% | -65.69% | -56.41% |
| EPS Basic | -95.68% | -76.93% | -65.84% | -44.24% | -23.49% |
| Normalized Basic EPS | -95.48% | -76.74% | -65.64% | -52.11% | -28.83% |
| EPS Diluted | -95.68% | -76.93% | -65.84% | -44.24% | -23.49% |
| Normalized Diluted EPS | -95.48% | -76.74% | -65.64% | -52.11% | -28.83% |
| Average Basic Shares Outstanding | 10.81% | 11.34% | 13.75% | 15.96% | 23.62% |
| Average Diluted Shares Outstanding | 10.81% | 11.34% | 13.75% | 15.96% | 23.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |